Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Auspex Pharmaceuticals, Inc. | aspx-ex991_2015031628.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 16, 2015
Auspex Pharmaceuticals, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
Delaware |
001-36292 |
95-4862842 |
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
|
3333 N. Torrey Pines Court, Suite 400 San Diego, California |
|
92037 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: (858) 558-2400
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02 Results of Operations and Financial Condition
On March 16, 2015, Auspex Pharmaceuticals, Inc. issued a press release announcing its financial results for the three and twelve months ended December 31, 2014. A copy of the press release is attached hereto as Exhibit 99.1.
The information in this Item and the exhibit attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether filed before or after the date hereof and regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits
(d)Exhibits
|
Exhibit |
|
Description |
|
99.1 |
|
Press Release of Auspex Pharmaceuticals, Inc. dated March 16, 2015 |
|
|
|
|
|
|
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
||
|
|
AUSPEX PHARMACEUTICALS, INC. |
||||
|
|
|
|
|||
|
|
By: |
|
/s/ Pratik Shah |
||
|
|
|
|
Pratik Shah, Ph.D. President and Chief Executive Officer |
||
EXHIBIT INDEX
|
Exhibit |
|
Description |
|
99.1 |
|
Press Release of Auspex Pharmaceuticals, Inc. dated March 16, 2015 |
|
|
|
|
|
|
|
|